Clinical Trial Update: Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating endoscopic ultrasound-guided radiofrequency ablation combined with pembrolizumab for locally advanced unresectable and metastatic pancr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: The University of Texas Health Science Center, Houston | Conditions: Pancreatic Ductal Adenocarcinoma | Phase 2 | Status: RECRUITING